Edwards Lifesciences Files 8-K on Financials
Ticker: EW · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1099800
| Field | Detail |
|---|---|
| Company | Edwards Lifesciences Corp (EW) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: EW
TL;DR
EDWARDS LIFESCIENCES FILED AN 8-K ON 10/24/24 DETAILING FINANCIALS.
AI Summary
Edwards Lifesciences Corporation filed an 8-K on October 24, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to this report.
Why It Matters
This 8-K filing provides crucial updates on Edwards Lifesciences' financial performance and condition, which can impact investor decisions and market perception.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Edwards Lifesciences Corporation (company) — Registrant
- October 24, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Irvine, California (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Edwards Lifesciences Corporation.
When was this 8-K filing submitted?
This 8-K filing was submitted on October 24, 2024.
What is the exact name of the company filing this report?
The exact name of the company is Edwards Lifesciences Corporation.
In which state was Edwards Lifesciences Corporation incorporated?
Edwards Lifesciences Corporation was incorporated in Delaware.
What are the principal executive offices of Edwards Lifesciences Corporation?
The principal executive offices of Edwards Lifesciences Corporation are located at One Edwards Way, Irvine, California, 92614.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-10-24 16:28:37
Key Financial Figures
- $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchange
Filing Documents
- ew-20241024.htm (8-K) — 35KB
- ex-991q32024.htm (EX-99.1) — 443KB
- ew45percentblacklrga21.jpg (GRAPHIC) — 625KB
- 0001099800-24-000084.txt ( ) — 1483KB
- ew-20241024.xsd (EX-101.SCH) — 2KB
- ew-20241024_lab.xml (EX-101.LAB) — 21KB
- ew-20241024_pre.xml (EX-101.PRE) — 12KB
- ew-20241024_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 24, 2024, Edwards Lifesciences Corporation, a Delaware corporation ("Edwards"), issued a press release setting forth Edwards' financial results for the third quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated October 24, 2024, reporting Edwards' financial results for the third quarter of 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 24, 2024 EDWARDS LIFESCIENCES CORPORATION By: /s/ Scott B. Ullem Scott B. Ullem Chief Financial Officer 3 Exhibit Index Exhibit Number Description 99.1 Press release, dated October 24, 2024, reporting Edwards' financial results for the third quarter of 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 4